6696 Stock Overview
A drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lin BioScience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$91.80 |
| 52 Week High | NT$153.50 |
| 52 Week Low | NT$70.00 |
| Beta | -0.014 |
| 1 Month Change | -6.71% |
| 3 Month Change | -15.39% |
| 1 Year Change | -40.20% |
| 3 Year Change | -60.60% |
| 5 Year Change | 144.15% |
| Change since IPO | 87.31% |
Recent News & Updates
Shareholder Returns
| 6696 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | -1.5% |
| 1Y | -40.2% | -9.5% | 25.5% |
Return vs Industry: 6696 underperformed the TW Biotechs industry which returned -9.5% over the past year.
Return vs Market: 6696 underperformed the TW Market which returned 25.5% over the past year.
Price Volatility
| 6696 volatility | |
|---|---|
| 6696 Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in TW Market | 8.6% |
| 10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 6696 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6696's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.linbioscience.com |
Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary and metastatic brain tumors; and LBS-009, an oral therapy for the treatment of non-alcoholic fatty liver disease and type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Lin BioScience, Inc. Fundamentals Summary
| 6696 fundamental statistics | |
|---|---|
| Market cap | NT$7.22b |
| Earnings (TTM) | -NT$687.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-10.5x
P/E RatioIs 6696 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6696 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$687.19m |
| Earnings | -NT$687.19m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6696 perform over the long term?
See historical performance and comparison